Comparison · NCT02576509-sae
Nivolumab 240 mg vs Sorafenib 400 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nivolumab 240 mg vs Sorafenib 400 mg: serious adverse events. Trial comparisons, record NCT02576509-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02576509-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.589 | 0.538 | 0.638 | wilson | |
| Risk in group 2 | 0.595 | 0.544 | 0.644 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00649 | -0.0774 | 0.0645 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.877 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 0.974 | 0.725 | 1.31 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Nivolumab 240 mg than on Sorafenib 400 mg | 154 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nivolumab 240 mg | Nivolumab 240 mg intravenously (IV) every 2 weeks until disease progression or unacceptable toxicity | 216 | 367 | EG000 |
| Group 2 | Sorafenib 400 mg | Sorafenib 400 mg orally (PO) twice a day (BID) until disease progression or unacceptable toxicity | 216 | 363 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All cause mortality was collected from randomization up to last survival follow up (approximately up to 98 months). Serious and non-serious adverse events were collected from first dose till 100 days after last dose of study therapy (up to approximately 95 months).
Source ClinicalTrials.gov
Trial
- Title
- An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
- NCT number
- NCT02576509
- Phases
- PHASE3
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Sorafenib
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2020-06-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02576509?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02576509-sae